PHARMACOKINETICS AND BIOAVAILABILITY OF MEDROXYPROGESTERONE ACETATE IN THE DOG AND THE RAT

被引:3
|
作者
SMITH, D [1 ]
ENEVER, R [1 ]
DEY, M [1 ]
LATTA, D [1 ]
WEIERSTALL, R [1 ]
机构
[1] WYETH AYERST RES,DRUG SAFETY EVALUAT,CHAZY,NY 12921
关键词
MEDROXYPROGESTERONE ACETATE; PHARMACOKINETICS; BIOAVAILABILITY; WEIBULL FUNCTION;
D O I
10.1002/bdd.2510140407
中图分类号
R9 [药学];
学科分类号
1007 ;
摘要
Medroxyprogesterone acetate (MPA) has been administered to rats and dogs. Dogs received single oral doses of 2 - 5, 5, and 10 mg MPA and a single intravenous dose of 1 mg MPA. Rats received single oral doses of 0 . 2, 1, 5, and 20 mg kg-1 MPA and multiple oral doses (14 daily doses) of 0 . 2, 5, and 20 mg kg-1 MPA. Dog plasma MPA levels from the intravenous dose were characterized by a triexponential decay with disposition half-lives of 0 - 3, 1.8, and 21.6 h. A Loo-Riegelman analysis of the dog plasma MPA levels from oral doses indicated absorption was not a simple first-order process. The Weibull Function was used to characterize the absorption kinetics of MPA. The oral absorption of MPA in dogs appears to be dose-linear over the dosage range studied, and the absolute bioavailability was estimated at 27 per cent. Rat plasma MPA levels from single and multiple oral doses were analyzed by a non-compartmental approach. AUC and C(max) values were not dose-linear over the dosage range studied; indicative of the self-induced metabolism of MPA. Exposure of similar dosages of MPA to both the rat and the dog resulted in similar plasma profiles and pharmacokinetics.
引用
收藏
页码:341 / 355
页数:15
相关论文
共 50 条
  • [31] REVERSIBILITY OF RAT-LIVER CIRRHOSIS BY MEDROXYPROGESTERONE ACETATE
    STENBACK, F
    SAARNI, HU
    RAUTIO, A
    STENGARD, J
    SOTANIEMI, EA
    TOXICOLOGIC PATHOLOGY, 1989, 17 (01) : 38 - 45
  • [32] PHARMACOKINETICS AND PHARMACODYNAMICS OF MEDROXYPROGESTERONE ACETATE IN ADVANCED BREAST-CANCER PATIENTS
    ETIENNE, MC
    MILANO, G
    FRENAY, M
    RENEE, N
    FRANCOIS, E
    THYSS, A
    SCHNEIDER, M
    NAMER, M
    JOURNAL OF CLINICAL ONCOLOGY, 1992, 10 (07) : 1176 - 1182
  • [33] INHIBITION OF CANALIZATION IN RAT SEMINIFEROUS CORDS BY MEDROXYPROGESTERONE ACETATE
    BRESSLER, RS
    SATYASWAROOP, PG
    INTERNATIONAL JOURNAL OF ANDROLOGY, 1978, 1 (04): : 371 - 377
  • [34] EFFECT OF MEDROXYPROGESTERONE ACETATE ON ADULT RAT OVARIES AND ADRENALS
    FARIAS, E
    DAHL, V
    BERGADA, C
    MEDICINA-BUENOS AIRES, 1974, 34 (01) : 19 - 24
  • [35] PHARMACOKINETICS OF AMEZINIUM IN RAT AND DOG
    TRAUT, M
    BRODE, E
    NEUMANN, B
    KUMMER, H
    ARZNEIMITTEL-FORSCHUNG/DRUG RESEARCH, 1981, 31-2 (9A): : 1594 - 1604
  • [36] THE PHARMACOKINETICS OF PIRTENIDINE IN THE RAT AND DOG
    POWLES, P
    USANSKY, JI
    FRANKLIN, RA
    XENOBIOTICA, 1989, 19 (12) : 1349 - 1354
  • [37] PHARMACOKINETICS OF DROXICAM IN RAT AND DOG
    ESTEVE, A
    MARTINEZ, L
    ROSER, R
    SAGARRA, R
    METHODS AND FINDINGS IN EXPERIMENTAL AND CLINICAL PHARMACOLOGY, 1986, 8 (07): : 423 - 429
  • [38] PHARMACOKINETICS AND BIOAVAILABILITY OF DILTIAZEM (CRD-401) IN DOG
    KOHNO, K
    TAKEUCHI, Y
    ETOH, A
    NODA, K
    ARZNEIMITTEL-FORSCHUNG/DRUG RESEARCH, 1977, 27 (07): : 1424 - 1428
  • [39] PHARMACOKINETICS OF CYANAMIDE IN DOG AND RAT
    OBACH, R
    COLOM, H
    ARSO, J
    PERAIRE, C
    PRUNONOSA, J
    JOURNAL OF PHARMACY AND PHARMACOLOGY, 1989, 41 (09) : 624 - 627
  • [40] PHARMACOKINETICS AND BIOAVAILABILITY OF BETA-SITOSTEROL IN THE BEAGLE DOG
    RITSCHEL, WA
    KASTNER, U
    HUSSAIN, AS
    KOCH, HP
    ARZNEIMITTEL-FORSCHUNG/DRUG RESEARCH, 1990, 40-1 (04): : 463 - 468